期刊
WOMENS HEALTH
卷 4, 期 3, 页码 229-231出版社
SAGE PUBLICATIONS LTD
DOI: 10.2217/17455057.4.3.229
关键词
adjuvant therapy; aromatase inhibitors; breast cancer; ErbB2; tamoxifen
资金
- Norvartis
- AstraZeneca
- Pfizer
This study analysed data after a median of 51 months follow-up from 4922 postmenopausal women with early hormone-sensitive breast cancer randomly assigned to 5 years of treatment with letrozole or tamoxifen. Tumors from 3650 (74%) patients were centrally assessed for estrogen receptor, progesterone receptor and ErbB2 status. By central assessment, 7% (257 of 3650) of tumors were classified as ErbB2-positive. Disease-free survival was significantly worse in patients with ErbB2-positive tumors (p < 0.0001). Letrozole improved disease-free survival compared with tamoxifen regardless of ErbB2 status.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据